NDC 70645-627 Gen7t


NDC Product Code 70645-627

NDC CODE: 70645-627

Proprietary Name: Gen7t What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Lidocaine What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • This medication is used to relieve nerve pain after shingles (infection with the herpes zoster virus). This type of pain is called post-herpetic neuralgia. Lidocaine helps to reduce sharp/burning/aching pain as well as discomfort caused by skin areas that are overly sensitive to touch. Lidocaine belongs to a class of drugs known as local anesthetics. It works by causing a temporary loss of feeling in the area where you apply the patch.

NDC Code Structure

NDC 70645-627-35

Package Description: 120 g in 1 BOTTLE

NDC Product Information

Gen7t with NDC 70645-627 is a a human prescription drug product labeled by 7t Pharma Llc. The generic name of Gen7t is lidocaine. The product's dosage form is lotion and is administered via topical form.

Labeler Name: 7t Pharma Llc

Dosage Form: Lotion - An emulsion, liquid1 dosage form. This dosage form is generally for external application to the skin.2

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Gen7t Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • LIDOCAINE 3.5 g/100g

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • WATER (UNII: 059QF0KO0R)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
  • Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Amide Local Anesthetic - [EPC] (Established Pharmacologic Class)
  • Amides - [CS]
  • Antiarrhythmic - [EPC] (Established Pharmacologic Class)
  • Local Anesthesia - [PE] (Physiologic Effect)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: 7t Pharma Llc
Labeler Code: 70645
Marketing Category: UNAPPROVED DRUG OTHER - What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 09-01-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Gen7t Product Label Images

Gen7t Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index


  • 1. Do not use: On the face or rashesOn wounds, damaged or infected skinOn eyes, mouth, genitals, or other mucous membranesWith a bandage or heating pad2. Consult physician for children under 12 years of age3. Stop and consult your prescriberIf pain worsensIf you are allergic to any of the ingredients in this productIf excessive skin irritation developsIf using concurrently with any other external pain-relieving productsIf you are pregnant, planning to become pregnant, or breastfeedingIf symptoms persist for more than 7 days, or symptoms clear up and occur again within 3 daysCall your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you:Shortness of breathSwelling or numbness of the tongue or throatSevere headache or vomitingDizziness or faintness Changes in vision or speechExcessive dosage, or short interval between doses, can result in high plasma levels and serious adverse effects. Patients should be instructed to strictly adhere to the recommended dosage and administration guidelines set forth in this literature and on your prescription label. The management of serious adverse reactions may require the use of resuscitative equipment, oxygen or other resuscitative drugs.General information about the safe and effective use Gen7T Lotion® Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use this product for another indication unless instructed and prescribed by a physician. Do not give this drug to anyone else, even if they have the same condition. This product is intended for use as prescribed by a physician. How should I store Gen7T Lotion®Store product at room temperature at 68°F to 77°F (20°C to 25°C). Keep away from heat or sunlight. Protect from excessive moisture. Safely discard product after expiration date posted on the product label. Discard this product away from small children or animals. DO NOT use the product after the expiration date printed on the bottle.What are the active ingredients in Gen7T Lotion® ?The lotion consists of 3.5% lidocaine.

Inactive Ingredients:

Phenoxyethanol, Ethylhexylglycerin, Water, Glycerin, Disodium EDTA, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Caprylic/Capric Triglycerides, Triethanolamine


Gen7T Lotion® is a prescription topical lotion containing 120 grams in a bottle. Lidocaine is present in a 3.5% concentration (w/w). It is chemically designated as 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide and has an empirical formula of C14H22N2O. The molecular weight of lidocaine is 234.34 g/mol. The structural formulas are: ** Lidocaine**

Clinical Pharmacology:

Lidocaine is a topical anesthetic and stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.


Gen7T Lotion® is contraindicated in patients with a known hypersensitivity to lidocaine, or any of the topical amide-like local anesthetic preparations or to any other component of the product.


Because of the possibility of sedation, patients should be cautioned regarding the operation of heavy machinery or automobiles, and any activities made hazardous by decreased alertness.Hepatic Disease: Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of Lidocaine, because of their inability to metabolize Lidocaine normally. Allergic Reactions: Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to Lidocaine. However, this product should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain. Non-intact Skin: Application to broken or inflamed skin, although not tested, may result in higher blood concentrations of Lidocaine from increased absorption. Gen7T Lotion® is only recommended for use on intact skin. Eye Exposure: The contact of this product with the eyes, although not studied, should be avoided based on the findings of severe eye irritations with the use of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns. External Heat Sources: Placement of external heat sources, such as heating pads or electric blankets, over application area is not recommended as this has not been evaluated and may increase plasma Lidocaine levels.

Drug Interactions:

Antiarrhythmic Drugs: Gen7T Lotion® should be used with caution in patients receiving Class 1 antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Gen7T Lotion® is used concurrently with other products containing local anesthetic agents the amount absorbed from all formulations must be considered.

Carcinogenesis, Mutagenesis, Impairment Of Fertility:

A minor metabolite, 2,6-xylidine, has been found to be carcinogenic in rats. The blood concentration of this metabolite is negligible following application topical lidocaine. The effect of Gen7T Lotion® on fertility has not been studied.


The safety of Gen7T Lotion® has not been established during pregnancy. There are no well-controlled studies in pregnant women. Gen7T Lotion® should not be used during pregnancy unless absolutely needed and discussed with a physician.

Nursing Mothers:

The effect of Gen7T Lotion® on the nursing infant has not been evaluated. Caution should be exercised when Gen7T Lotion® is administered to a nursing mother.

Pediatric / Geriatric Use:

Safety and effectiveness in pediatric and geriatric patients have not been established.

Adverse Reactions:

The most common adverse reactions are application site reactions, including dermatitis, itching or scaling. These tend to be dose-limiting and diminish with time. Serious adverse experiences following the administration of Gen7T Lotion® are similar in nature to those observed in other amide anesthetic-containing agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption, or may result from hypersensitivity, idiosyncrasy, or a diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature.


There have been no reports of over-dosage with Gen7T Lotion®. Signs of overdosage would include vomiting, drowsiness, coma, respiratory depression, and seizures. In the case of an overdosage, discontinue the product immediately, treat the patient symptomatically, and institute supportive measures.

How Supplied:

Gen7T Lotion® is supplied in the following dosage form:120 gramsMade in USARx OnlyManufactured for: 7T Pharma, LLC220 Emerald Vista WayLas Vegas, NV 89144800.941.2848NDC: 70645-627-35 Size: 120 grams

* Please review the disclaimer below.